

# Valentina Guarneri

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3533071/publications.pdf>

Version: 2024-02-01

168  
papers

7,367  
citations

87843

38  
h-index

66879

78  
g-index

170  
all docs

170  
docs citations

170  
times ranked

8716  
citing authors

#	ARTICLE	IF	CITATIONS
1	Frequency and Risk Factors Associated With Osteonecrosis of the Jaw in Cancer Patients Treated With Intravenous Bisphosphonates. <i>Journal of Bone and Mineral Research</i> , 2008, 23, 826-836.	3.1	527
2	Prognostic Value of Pathologic Complete Response After Primary Chemotherapy in Relation to Hormone Receptor Status and Other Factors. <i>Journal of Clinical Oncology</i> , 2006, 24, 1037-1044.	0.8	514
3	Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2 <sup>+</sup> , Node-Positive, High-Risk, Early Breast Cancer (monarchE). <i>Journal of Clinical Oncology</i> , 2020, 38, 3987-3998.	0.8	478
4	Trastuzumab containing regimens for early breast cancer. <i>The Cochrane Library</i> , 2021, 2021, CD006243.	1.5	340
5	Long-Term Cardiac Tolerability of Trastuzumab in Metastatic Breast Cancer: The M.D. Anderson Cancer Center Experience. <i>Journal of Clinical Oncology</i> , 2006, 24, 4107-4115.	0.8	336
6	Preoperative Chemotherapy Plus Trastuzumab, Lapatinib, or Both in Human Epidermal Growth Factor Receptor 2 <sup>+</sup> Positive Operable Breast Cancer: Results of the Randomized Phase II CHER-LOB Study. <i>Journal of Clinical Oncology</i> , 2012, 30, 1989-1995.	0.8	330
7	Phase II Clinical Trial of Ixabepilone (BMS-247550), an Etoposide Analog, in Patients With Taxane-Resistant Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, 3399-3406.	0.8	273
8	Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer. <i>Breast Cancer Research and Treatment</i> , 2010, 122, 181-188.	1.1	232
9	Safety of Intravenous and Oral Bisphosphonates and Compliance With Dosing Regimens. <i>Oncologist</i> , 2004, 9, 28-37.	1.9	203
10	Circulating Tumor Cells in Metastatic Breast Cancer: Biologic Staging Beyond Tumor Burden. <i>Clinical Breast Cancer</i> , 2007, 7, 34-42.	1.1	141
11	Comparison of HER-2 and Hormone Receptor Expression in Primary Breast Cancers and Asynchronous Paired Metastases: Impact on Patient Management. <i>Oncologist</i> , 2008, 13, 838-844.	1.9	133
12	Rare Breast Cancer Subtypes: Histological, Molecular, and Clinical Peculiarities. <i>Oncologist</i> , 2014, 19, 805-813.	1.9	132
13	Trastuzumab-containing regimens for metastatic breast cancer. <i>The Cochrane Library</i> , 2021, 2021, CD006242.	1.5	128
14	The curability of breast cancer and the treatment of advanced disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2004, 31, S149-S161.	3.3	123
15	Immune Infiltrates in Breast Cancer: Recent Updates and Clinical Implications. <i>Cells</i> , 2021, 10, 223.	1.8	115
16	Agreement between MRI and pathologic breast tumor size after neoadjuvant chemotherapy, and comparison with alternative tests: individual patient data meta-analysis. <i>BMC Cancer</i> , 2015, 15, 662.	1.1	106
17	Concomitant versus sequential administration of epirubicin and paclitaxel as first-line therapy in metastatic breast carcinoma. <i>Cancer</i> , 2004, 101, 704-712.	2.0	105
18	Metastatic Breast Cancer: Therapeutic Options According to Molecular Subtypes and Prior Adjuvant Therapy. <i>Oncologist</i> , 2009, 14, 645-656.	1.9	98

#	ARTICLE	IF	CITATIONS
19	HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade. <i>Journal of the National Cancer Institute</i> , 2020, 112, 46-54.	3.0	97
20	Evolution of HER2-low expression from primary to recurrent breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 137.	2.3	94
21	HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2020, 84, 101965.	3.4	92
22	Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer. <i>Oncologist</i> , 2015, 20, 1001-1010.	1.9	85
23	The immune system and hormone-receptor positive breast cancer: Is it really a dead end?. <i>Cancer Treatment Reviews</i> , 2016, 46, 9-19.	3.4	84
24	Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status. <i>Journal of Ovarian Research</i> , 2019, 12, 9.	1.3	83
25	Renal Safety and Efficacy of i.v. Bisphosphonates in Patients with Skeletal Metastases Treated for up to 10 Years. <i>Oncologist</i> , 2005, 10, 842-848.	1.9	82
26	Real world data in the era of Immune Checkpoint Inhibitors (ICIs): Increasing evidence and future applications in lung cancer. <i>Cancer Treatment Reviews</i> , 2020, 87, 102031.	3.4	82
27	Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer. , 2019, 7, 90.		80
28	Achievements and unmet needs in the management of advanced ovarian cancer. <i>Gynecologic Oncology</i> , 2010, 117, 152-158.	0.6	78
29	Enhancing intracellular taxane delivery: current role and perspectives of nanoparticle albumin-bound paclitaxel in the treatment of advanced breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 395-406.	0.9	70
30	Immune characterization of breast cancer metastases: prognostic implications. <i>Breast Cancer Research</i> , 2018, 20, 62.	2.2	54
31	Multicentric, Randomized Phase III Trial of Two Different Adjuvant Chemotherapy Regimens plus Three Versus Twelve Months of Trastuzumab in Patients with HER2-Positive Breast Cancer (Short-HER Trial); Tj ETQq1 1 01784314 152 / Over		52
32	A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation. <i>Lancet Oncology</i> , The, 2020, 21, 1455-1464.	5.1	52
33	Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relatives. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 140, 67-72.	2.0	51
34	Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer. <i>EBioMedicine</i> , 2022, 75, 103801.	2.7	47
35	Double-Blind, Placebo-Controlled, Multicenter, Randomized, Phase IIB Neoadjuvant Study of Letrozole-Lapatinib in Postmenopausal Hormone Receptorâ€“Positive, Human Epidermal Growth Factor Receptor 2â€“Negative, Operable Breast Cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 1050-1057.	0.8	46
36	Mesenchymal Progenitors Expressing <scp>TRAIL</scp> Induce Apoptosis in Sarcomas. <i>Stem Cells</i> , 2015, 33, 859-869.	1.4	46

#	ARTICLE	IF	CITATIONS
37	18F-Fluoroestradiol Positron Emission Tomography in Breast Cancer Patients: Systematic Review of the Literature & Meta-Analysis. <i>Current Radiopharmaceuticals</i> , 2016, 9, 244-257.	0.3	46
38	HER2-low-positive breast cancer: evolution from primary tumor to residual disease after neoadjuvant treatment. <i>Npj Breast Cancer</i> , 2022, 8, .	2.3	46
39	Impact of estrogen receptor levels on outcome in non-metastatic triple negative breast cancer patients treated with neoadjuvant/adjuvant chemotherapy. <i>Npj Breast Cancer</i> , 2021, 7, 101.	2.3	44
40	Androgen Receptor Expression and Association With Distant Disease-Free Survival in Triple Negative Breast Cancer: Analysis of 263 Patients Treated With Standard Therapy for Stage I-III Disease. <i>Frontiers in Oncology</i> , 2019, 9, 452.	1.3	43
41	Biomarkers for HER2-positive metastatic breast cancer: Beyond hormone receptors. <i>Cancer Treatment Reviews</i> , 2020, 88, 102064.	3.4	41
42	Relapsed Triple-Negative Breast Cancer: Challenges and Treatment Strategies. <i>Drugs</i> , 2013, 73, 1257-1265.	4.9	40
43	Myelopoiesis, metabolism and therapy: a crucial crossroads in cancer progression. <i>Cell Stress</i> , 2019, 3, 284-294.	1.4	40
44	Whole exome sequencing of rare aggressive breast cancer histologies. <i>Breast Cancer Research and Treatment</i> , 2016, 156, 21-32.	1.1	38
45	GD2 expression in breast cancer. <i>Oncotarget</i> , 2017, 8, 31592-31600.	0.8	38
46	Detection of microparticles from human red blood cells by multiparametric flow cytometry. <i>Blood Transfusion</i> , 2015, 13, 274-80.	0.3	38
47	Olaparib for the treatment of breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 519-530.	1.1	37
48	Programmed Cell Death Ligand 1 in Breast Cancer: Technical Aspects, Prognostic Implications, and Predictive Value. <i>Oncologist</i> , 2019, 24, e1055-e1069.	1.9	36
49	Cancer and COVID-19: what do we really know?. <i>Lancet, The</i> , 2020, 395, 1884-1885.	6.3	36
50	Neoadjuvant Chemotherapy and Immunotherapy in Luminal B-like Breast Cancer: Results of the Phase II GIADA Trial. <i>Clinical Cancer Research</i> , 2022, 28, 308-317.	3.2	36
51	Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I-III patients treated with standard therapy. <i>European Journal of Cancer</i> , 2020, 136, 7-15.	1.3	32
52	Bevacizumab Treatment for Advanced Breast Cancer. <i>Oncologist</i> , 2011, 16, 1684-1697.	1.9	31
53	External validation of Modified Breast Graded Prognostic Assessment for breast cancer patients with brain metastases: A multicentric European experience. <i>Breast</i> , 2018, 37, 36-41.	0.9	31
54	Clinicopathological and Treatment-Associated Prognostic Factors in Patients with Breast Cancer Leptomeningeal Metastases in Relation to Tumor Biology. <i>Oncologist</i> , 2018, 23, 1289-1299.	1.9	31

#	ARTICLE	IF	CITATIONS
55	Preoperative Chemotherapy plus Lapatinib or Trastuzumab or Both in HER2-Positive Operable Breast Cancer (CHERLOB Trial). <i>Clinical Breast Cancer</i> , 2008, 8, 192-194.	1.1	29
56	Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies. <i>ESMO Open</i> , 2022, 7, 100459.	2.0	26
57	First-Line Osimertinib in Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER Study. <i>Oncologist</i> , 2022, 27, 87-e115.	1.9	25
58	The Tumor Microenvironment of Primitive and Metastatic Breast Cancer: Implications for Novel Therapeutic Strategies. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8102.	1.8	24
59	Primary systemic therapy for operable breast cancer: A review of clinical trials and perspectives. <i>Cancer Letters</i> , 2007, 248, 175-185.	3.2	23
60	SAFE trial: an ongoing randomized clinical study to assess the role of cardiotoxicity prevention in breast cancer patients treated with anthracyclines with or without trastuzumab. <i>Medical Oncology</i> , 2017, 34, 75.	1.2	23
61	Downregulation of the Cyclin-Dependent Kinase Inhibitor p27kip1 Might Correlate with Poor Disease-Free and Overall Survival in Inflammatory Breast Cancer. <i>Clinical Breast Cancer</i> , 2006, 7, 326-330.	1.1	22
62	Impact of 21-Gene Breast Cancer Assay on Treatment Decision for Patients with T1-T3, N0-N1, Estrogen Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer: Final Results of the Prospective Multicenter ROXANE Study. <i>Oncologist</i> , 2019, 24, 1424-1431.	1.9	22
63	Phase III randomized study of adjuvant treatment with the ANTI-PD-L1 antibody avelumab for high-risk triple negative breast cancer patients: The A-BRAVE trial. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS598-TPS598.	0.8	22
64	Recommendations for the implementation of BRCA testing in the care and treatment pathways of ovarian cancer patients. <i>Future Oncology</i> , 2016, 12, 2071-2075.	1.1	21
65	Implications of metabolism-driven myeloid dysfunctions in cancer therapy. <i>Cellular and Molecular Immunology</i> , 2021, 18, 829-841.	4.8	21
66	Neoadjuvant approach as a platform for treatment personalization: focus on HER2-positive and triple-negative breast cancer. <i>Cancer Treatment Reviews</i> , 2021, 98, 102222.	3.4	21
67	Impact of neoadjuvant single or dual HER2 inhibition and chemotherapy backbone upon pathological complete response in operable and locally advanced breast cancer: Sensitivity analysis of randomized trials. <i>Cancer Treatment Reviews</i> , 2014, 40, 847-856.	3.4	20
68	Trastuzumab-lapatinib as neoadjuvant therapy for HER2-positive early breast cancer: Survival analyses of the ChER-lob trial. <i>European Journal of Cancer</i> , 2021, 153, 133-141.	1.3	20
69	Definition of High-Risk Early Hormone-Positive HER2-Negative Breast Cancer: A Consensus Review. <i>Cancers</i> , 2022, 14, 1898.	1.7	20
70	Phase II, randomized trial of preoperative epirubicin-paclitaxel+gefitinib with biomarker evaluation in operable breast cancer. <i>Breast Cancer Research and Treatment</i> , 2008, 110, 127-134.	1.1	19
71	Hormone receptors status: a strong determinant of the kinetics of brain metastases occurrence compared with HER2 status in breast cancer. <i>Journal of Neuro-Oncology</i> , 2018, 138, 369-382.	1.4	19
72	BMI is an independent prognostic factor for late outcome in patients diagnosed with early breast cancer: A landmark survival analysis. <i>Breast</i> , 2019, 47, 77-84.	0.9	19

#	ARTICLE	IF	CITATIONS
73	Therapeutic Strategies for the Management of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Positive (HR+/HER2+) Breast Cancer: A Review of the Current Literature. <i>Cancers</i> , 2020, 12, 3317.	1.7	19
74	PIK3CA Mutation in the ShortHER Randomized Adjuvant Trial for Patients with Early HER2+ Breast Cancer: Association with Prognosis and Integration with PAM50 Subtype. <i>Clinical Cancer Research</i> , 2020, 26, 5843-5851.	3.2	17
75	Gene-expression signatures to inform neoadjuvant treatment decision in HR+/HER2- breast cancer: Available Evidence and Clinical Implications. <i>Cancer Treatment Reviews</i> , 2021, 102, 102323.	3.4	17
76	Magnetic Resonance Imaging and Ultrasonography in Predicting Infiltrating Residual Disease after Preoperative Chemotherapy in Stage II-III Breast Cancer. <i>Annals of Surgical Oncology</i> , 2011, 18, 2150-2157.	0.7	16
77	Could semiquantitative FDG analysis add information to the prognosis in patients with stage II/III breast cancer undergoing neoadjuvant treatment?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 1648-1655.	3.3	16
78	Prognostic impact of proliferation for resected early stage "pure" invasive lobular breast cancer: Cut-off analysis of Ki67 according to histology and clinical validation. <i>Breast</i> , 2017, 35, 21-26.	0.9	16
79	Letrozole Versus Letrozole plus Lapatinib (GW572016) in Hormone-Sensitive, HER2-Negative Operable Breast Cancer: A Double-Blind, Randomized, Phase II Study with Biomarker Evaluation (EGF109077-LAP107692/LETLOB). <i>Clinical Breast Cancer</i> , 2008, 8, 97-100.	1.1	15
80	Should triple-positive breast cancer be recognized as a distinct subtype?. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 1011-1014.	1.1	15
81	Epidemiology and clinical course of severe acute respiratory syndrome coronavirus 2 infection in cancer patients in the Veneto Oncology Network: The Rete Oncologica Veneta covid19 study. <i>European Journal of Cancer</i> , 2021, 147, 120-127.	1.3	15
82	Blurring of boundaries in the doctor-patient relationship. <i>Lancet Oncology</i> , The, 2014, 15, 1423-1424.	5.1	14
83	Preoperative Carboplatin-Paclitaxel-Bevacizumab in Triple-Negative Breast Cancer: Final Results of the Phase II Ca.Pa.Be Study. <i>Annals of Surgical Oncology</i> , 2015, 22, 2881-2887.	0.7	14
84	Therapeutic perspectives for brain metastases in non-oncogene addicted non-small cell lung cancer (NSCLC): Towards a less dismal future?. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 128, 19-29.	2.0	14
85	Prognostic factors in phyllodes tumours of the breast: retrospective study on 166 consecutive cases. <i>ESMO Open</i> , 2020, 5, e000843.	2.0	14
86	Prognostic Factors in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Advanced Breast Cancer: A Systematic Literature Review. <i>Cancer Management and Research</i> , 2021, Volume 13, 6537-6566.	0.9	14
87	Clinical features and treatment outcome of non-small cell lung cancer (NSCLC) patients with uncommon or complex epidermal growth factor receptor (EGFR) mutations. <i>Oncotarget</i> , 2017, 8, 32626-32638.	0.8	14
88	Evolving Nonendocrine Therapeutic Options for Metastatic Breast Cancer: How Adjuvant Chemotherapy Influences Treatment. <i>Clinical Breast Cancer</i> , 2007, 7, 841-849.	1.1	13
89	Predictors of human epidermal growth factor receptor 2 fluorescence in-situ hybridisation amplification in immunohistochemistry score 2+ infiltrating breast cancer: a single institution analysis. <i>Journal of Clinical Pathology</i> , 2012, 65, 503-506.	1.0	13
90	Use of scalp cooling device to prevent alopecia for early breast cancer patients receiving chemotherapy: A prospective study. <i>Breast Journal</i> , 2020, 26, 1296-1301.	0.4	13

#	ARTICLE	IF	CITATIONS
91	Diagnostic and prognostic impact of fluorine-18-fluorodeoxyglucose PET/CT in preoperative and postoperative setting of breast cancer patients. <i>Nuclear Medicine Communications</i> , 2017, 38, 537-545.	0.5	12
92	Treatment strategies for locally advanced non-small cell lung cancer in elderly patients: Translating scientific evidence into clinical practice. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 163, 103378.	2.0	12
93	Timing for starting second-line therapy in recurrent ovarian cancer. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 49-55.	1.1	11
94	Career opportunities and benefits for young oncologists in the European Society for Medical Oncology (ESMO). <i>ESMO Open</i> , 2016, 1, e000107.	2.0	11
95	Escalation and de-escalation in HER2 positive early breast cancer. <i>Current Opinion in Oncology</i> , 2019, 31, 35-42.	1.1	11
96	Use of Electronic Administrative Databases to Measure Quality Indicators of Breast Cancer Care: Experience of Five Regional Oncology Networks in Italy. <i>JCO Oncology Practice</i> , 2020, 16, e211-e220.	1.4	11
97	Tumor Stroma Manipulation By MSC. <i>Current Drug Targets</i> , 2016, 17, 1111-1126.	1.0	11
98	Triple-negative breast cancer: current management and future options. <i>European Journal of Cancer</i> , Supplement, 2009, 7, 14-18.	2.2	10
99	Primary pulmonary cancer colliding with metastatic breast carcinoma: Hitherto unreported cases of cancer-to-cancer metastasis focusing on clinical implications. <i>Lung Cancer</i> , 2011, 74, 145-148.	0.9	10
100	The Next Generation of Biologic Agents: Therapeutic Role in Relation to Existing Therapies in Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2012, 12, 157-166.	1.1	10
101	Tumor size, node status, grading, HER2 and estrogen receptor status still retain a strong value in patients with operable breast cancer diagnosed in recent years. <i>International Journal of Cancer</i> , 2013, 132, E58-65.	2.3	10
102	Results of the ECHO (Eating habits CHanges in Oncologic patients) Survey: An Italian Cross-Sectional Multicentric Study to Explore Dietary Changes and Dietary Supplement Use, in Breast Cancer Survivors. <i>Frontiers in Oncology</i> , 2021, 11, 705927.	1.3	10
103	Safety of autologous fat grafting in breast cancer: a multicenter Italian study among 17 senonetwork breast units autologous fat grafting safety: a multicenter Italian retrospective study. <i>Breast Cancer Research and Treatment</i> , 2022, 191, 355-363.	1.1	10
104	Lapatinib plus letrozole for postmenopausal patients with advanced HER2+/HR+breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2009, 9, 1549-1557.	1.1	9
105	Predictive and Prognostic Role of P53 According to Tumor Phenotype in Breast Cancer Patients Treated with Preoperative Chemotherapy: A Single-Institution Analysis. <i>International Journal of Biological Markers</i> , 2010, 25, 104-111.	0.7	9
106	Patterns of Fertility Preservation and Pregnancy Outcome After Breast Cancer at a Large Comprehensive Cancer Center. <i>Journal of Women's Health</i> , 2019, 28, 544-550.	1.5	9
107	Neoplastic Pericardial Effusion: A Monocentric Retrospective Study. <i>Journal of Palliative Medicine</i> , 2019, 22, 691-695.	0.6	9
108	Immune microenvironment and intrinsic subtyping in hormone receptor-positive/HER2-negative breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 12.	2.3	9

#	ARTICLE	IF	CITATIONS
109	Breast-Gynaecological & Immuno-Oncology International Cancer Conference (BGICC) Consensus and Recommendations for the Management of Triple-Negative Breast Cancer. <i>Cancers</i> , 2021, 13, 2262.	1.7	9
110	A comprehensive profiling of the immune microenvironment of breast cancer brain metastases. <i>Neuro-Oncology</i> , 2022, 24, 2146-2158.	0.6	9
111	Beyond breast specificâ€”Graded Prognostic Assessment in patients with brain metastases from breast cancer: treatment impact on outcome. <i>Journal of Neuro-Oncology</i> , 2017, 131, 369-376.	1.4	8
112	First Prospective Multicenter Italian Study on the Impact of the 21â€”Gene Recurrence Score in Adjuvant Clinical Decisions for Patients with ER Positive/HER2 Negative Breast Cancer. <i>Oncologist</i> , 2018, 23, 297-305.	1.9	8
113	Validation of Residual Proliferative Cancer Burden as a Predictor of Long-Term Outcome Following Neoadjuvant Chemotherapy in Patients with Hormone Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer. <i>Oncologist</i> , 2020, 25, e1355-e1362.	1.9	8
114	ESR1 Gene Mutation in Hormone Receptor-Positive HER2-Negative Metastatic Breast Cancer Patients: Concordance Between Tumor Tissue and Circulating Tumor DNA Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 625636.	1.3	8
115	How the COVID-19 Pandemic Impacted on Integrated Care Pathways for Lung Cancer: The Parallel Experience of a COVID-Spared and a COVID-Dedicated Center. <i>Frontiers in Oncology</i> , 2021, 11, 669786.	1.3	8
116	Nonâ€”Small-Cell Lung Cancer: Real-World Cost Consequence Analysis. <i>JCO Oncology Practice</i> , 2021, 17, e1085-e1093.	1.4	8
117	Everolimus plus aromatase inhibitors as maintenance therapy after first-line chemotherapy: Final results of the phase III randomised MAIN-A (MAINtenance Afinitor) trial. <i>European Journal of Cancer</i> , 2021, 154, 21-29.	1.3	8
118	Olaparib for advanced breast cancer. <i>Future Oncology</i> , 2020, 16, 717-732.	1.1	8
119	Quantitative expression of estrogen receptor on relapse biopsy for ER-positive breast cancer: prognostic impact. <i>Anticancer Research</i> , 2014, 34, 3657-62.	0.5	8
120	Exceptional and Durable Responses to TDM-1 After Trastuzumab Failure for Breast Cancer Skin Metastases: Potential Implications of an Immunological Sanctuary. <i>Frontiers in Oncology</i> , 2018, 8, 581.	1.3	7
121	Combined Immunoscore for Prognostic Stratification of Early Stage Non-Small-Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 564915.	1.3	7
122	SRC and PIM1 as potential co-targets to overcome resistance in MET deregulated non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2020, 9, 1810-1821.	1.3	7
123	Real-world data on treatment outcomes in EGFR-mutant non-small-cell lung cancer patients receiving osimertinib in second or further lines. <i>Future Oncology</i> , 2021, 17, 2513-2527.	1.1	7
124	Weekly Docetaxel/Paclitaxel in Pretreated Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2002, 3, 346-352.	1.1	6
125	Predictive Value of Biologic Parameters for Primary Chemotherapy in Operable Breast Cancer. <i>Clinical Breast Cancer</i> , 2005, 6, 315-324.	1.1	6
126	Biomarkers Predicting Clinical Benefit: Fact or Fiction?. <i>Journal of the National Cancer Institute Monographs</i> , 2011, 2011, 63-66.	0.9	6



#	ARTICLE	IF	CITATIONS
127	PIK3CA: a Target or a Marker in Breast Cancers. <i>Current Breast Cancer Reports</i> , 2015, 7, 161-169.	0.5	6
128	An Italian Delphi study to evaluate consensus on adjuvant endocrine therapy in premenopausal patients with breast cancer: the ERA project. <i>BMC Cancer</i> , 2018, 18, 932.	1.1	6
129	Netupitant/palonosetron (NEPA) and dexamethasone for prevention of emesis in breast cancer patients receiving adjuvant anthracycline plus cyclophosphamide: a multi-cycle, phase II study. <i>BMC Cancer</i> , 2020, 20, 232.	1.1	6
130	De-escalated treatment with trastuzumab-pertuzumab-letrozole in patients with HR+/HER2+ operable breast cancer with Ki67 response after 2 weeks letrozole: Final results of the PerELISA neoadjuvant study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 507-507.	0.8	6
131	Profiling of immune checkpoint biomarkers by multiplex immunofluorescence in breast cancer brain metastases.. <i>Journal of Clinical Oncology</i> , 2021, 39, 2021-2021.	0.8	5
132	Correlation of <i>PIK3CA</i> mutation with pathological complete response in primary HER2-positive breast cancer: Combined analysis of 967 patients from three prospective clinical trials.. <i>Journal of Clinical Oncology</i> , 2015, 33, 511-511.	0.8	5
133	Safety of COVID-19 Vaccine in Patients with Cancer in a High-Volume Comprehensive Cancer Center. <i>Oncologist</i> , 2022, 27, e203-e205.	1.9	5
134	The clinical relevance of endocrine therapy-induced changes in lipid metabolism in breast cancer patients. <i>Cancer Biology and Therapy</i> , 2009, 8, 1456-1458.	1.5	4
135	Maintenance therapy in epithelial ovarian cancer: from chemotherapy to targeted agents. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 1041-1050.	1.1	4
136	Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial. <i>BMC Medicine</i> , 2019, 17, 207.	2.3	4
137	Targeted next-generation sequencing identifies genomic abnormalities potentially driving the prognosis of early-stage invasive lobular breast carcinoma patients stratified according to a validated clinico-pathological model. <i>Breast</i> , 2020, 50, 56-63.	0.9	4
138	Impact of Baseline and On-Treatment Glycemia on Everolimus-Exemestane Efficacy in Patients with Hormone Receptor-Positive Advanced Breast Cancer (EVERMET). <i>Clinical Cancer Research</i> , 2021, 27, 3443-3455.	3.2	4
139	Detection of circulating immunosuppressive cytokines in malignant pleural mesothelioma patients for prognostic stratification. <i>Cytokine</i> , 2021, 146, 155622.	1.4	4
140	An overview of immune checkpoint inhibitors in breast cancer. <i>Exploration of Targeted Anti-tumor Therapy</i> , 2020, 1, .	0.5	4
141	In Response to Body Letter to the Editor Regarding "Safety of Intravenous and Oral Bisphosphonates and Compliance with Dosing Regimens". <i>Oncologist</i> , 2005, 10, 318-319.	1.9	3
142	Controversies of chemotherapy for the treatment of metastatic breast cancer. <i>European Journal of Cancer, Supplement</i> , 2007, 5, 11-16.	2.2	3
143	BRCA1/2 Molecular Assay for Ovarian Cancer Patients: A Survey through Italian Departments of Oncology and Molecular and Genomic Diagnostic Laboratories. <i>Diagnostics</i> , 2019, 9, 146.	1.3	3
144	Postsurgical Pyoderma Gangrenosum in a Breast Cancer Patient: A Case Report and Literature Review. <i>Case Reports in Oncology</i> , 2021, 14, 160-164.	0.3	3

#	ARTICLE	IF	CITATIONS
145	Histology-based Combination Induction Chemotherapy for Elderly Patients with Clinical Stage III Non-small Cell Lung Cancer. <i>Anticancer Research</i> , 2017, 37, 3723-3728.	0.5	3
146	OUP accepted manuscript. <i>Oncologist</i> , 2022, , .	1.9	3
147	Clinical profile and mortality of Sars-Cov-2 infection in cancer patients across two pandemic time periods (Feb 2020â€“Sep 2020; Sep 2020â€“May 2021) in the Veneto Oncology Network: The ROVID study. <i>European Journal of Cancer</i> , 2022, 167, 81-91.	1.3	3
148	Type of endocrine therapy and DFS in patients with early HER2+/HR+ BC: Analysis from the phase III randomized ShortHER trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 547-547.	0.8	3
149	In Response to Jackson Letter to the Editor Regarding â€œSafety of Intravenous and Oral Bisphosphonates and Compliance with Dosing Regimensâ€. <i>Oncologist</i> , 2005, 10, 315-316.	1.9	2
150	The Future of Chemotherapy in the Era of Personalized Medicine. <i>Current Breast Cancer Reports</i> , 2013, 5, 57-68.	0.5	2
151	The impact of adjuvant endocrine therapy in early breast cancer on quality-of-life: an overview of prospective trials. <i>Expert Review of Quality of Life in Cancer Care</i> , 2016, 1, 111-120.	0.6	2
152	Subacute Cutaneous Lupus Erythematosus-Like Eruption Induced by EGFR -Tyrosine Kinase Inhibitor in EGFR-Mutated Non-small Cell Lung Cancer: A Case Report. <i>Frontiers in Medicine</i> , 2021, 8, 570921.	1.2	2
153	Circulating cytokines as predictors of response to immune checkpoint inhibitors (ICIs) in patients (pts) with melanoma (Mel) and nonâ€“small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2022, 40, 2549-2549.	0.8	2
154	Clinical Utility of Measuring Circulating Tumor Cells in Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2006, 7, 85-86.	1.1	1
155	Epidemiology and clinical course of SARS-CoV-2 infection in cancer patients in the Veneto Oncology Network during the first and second pandemic waves.. <i>Journal of Clinical Oncology</i> , 2021, 39, 6511-6511.	0.8	1
156	Gastric metastases of breast cancer: Histopathological and molecular characterization of a single Institution case series. <i>Pathology Research and Practice</i> , 2022, 233, 153872.	1.0	1
157	Diagnostic-Therapeutic Pathway and Outcomes of Early Stage NSCLC: a Focus on EGFR Testing in the Real-World. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
158	CMET-29. HORMONE RECEPTORS STATUS: Aâ€“STRONG DETERMINANT OF THE KINETICS OF BRAIN METASTASES OCCURRENCE COMPARED WITH HER2 STATUS IN BREAST CANCER. <i>Neuro-Oncology</i> , 2017, 19, vi45-vi45.	0.6	0
159	HER2-Positive Early Breast Cancer. , 2019, , 371-382.		0
160	Abstract PS10-02: A good prognosis of endocrine-dependent tumors among residual invasive cancer after anti-HER2 therapy: CALGB 40601 (Alliance) and validation studies. , 2021, , .		0
161	Medication-related osteonecrosis of the jaw in patients with bone metastases from solid tumors: analysis of the Istituto Oncologico Veneto case series. <i>Qeios</i> , 0, , .	0.0	0
162	Locoregional and Locally Advanced Breast Cancer. <i>UNIPA Springer Series</i> , 2021, , 429-466.	0.1	0

#	ARTICLE	IF	CITATIONS
163	Targeted Therapies for HER2-positive Breast Cancer. <i>Current Clinical Pathology</i> , 2015, , 57-72.	0.0	0
164	Progress in the Treatment of Early and Advanced Breast Cancer. , 2008, , 239-256.		0
165	CTNI-33. METRONOMIC TEMOZOLOMIDE THERAPY IN HEAVILY PRETREATED PATIENTS WITH RECURRENT GLIOBLASTOMA: A LARGE MONO-INSTITUTIONAL RETROSPECTIVE STUDY. <i>Neuro-Oncology</i> , 2021, 23, vi66-vi67.	0.6	0
166	Tumor Immune-Infiltrate Landscape After Chemo-Radiotherapy in a Case Series of Patients with Non-small Cell Lung Cancer: Pretreatment Predictors and Correlation With Outcome. <i>Oncologist</i> , 2022, 27, e199-e202.	1.9	0
167	Exploratory radiomic analysis of stage III non-small cell lung cancer CT images: Correlation with clinical-pathological characteristics.. <i>Journal of Clinical Oncology</i> , 2022, 40, e20574-e20574.	0.8	0
168	Safety interim analysis (SIA) of atractib: A phase 2 trial of first-line (1L) atezolizumab (A) in combination with paclitaxel (P) and bevacizumab (B) in metastatic triple-negative breast cancer (mTNBC).. <i>Journal of Clinical Oncology</i> , 2022, 40, 1084-1084.	0.8	0